Non-Alcoholic Fatty Liver Disease Biochip
Non-Alcoholic Fatty Liver Disease (NAFLD) is a prevalent liver disease that affects people worldwide. It is more common in males than females, with an estimated global incidence of 47 cases per 1,000 population. Among adults, the global prevalence of NAFLD is estimated to be 32%, with a higher prevalence among males (40%) than females (26%). By 2023, it is predicted to be the most frequent indication for liver transplants. NAFLD occurs due to an ectopic accumulation in hepatocytes, which causes insulin resistance, chronic inflammation, progressive fibrosis, and an increased risk of hepatocellular carcinoma.
Currently, the diagnosis of NAFLD is made by ultrasound, and an invasive biopsy is needed for staging. Non-invasive biomarkers are required for staging and monitoring. Biochip array provides risk stratification to assess the different stages of Non-Alcoholic Fatty Liver Disease (NAFLD) preventing invasive biopsy and allowing timely and effective care.
Biochip Markers
Why use Biochip?
Benefits of the Evidence MultiSTAT
The Evidence MultiSTAT
Meet the Evidence MultiSTAT
The Evidence MultiSTAT is an easy to use, small footprint analyser facilitating on-site simultaneous detection of multiple biomarkers.
Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results.
With minimal sample preparation required, this versatile benchtop analyser can achieve accurate, quantitative results in minutes.
Meet the Cartridge
The Evidence MultiSTAT cartridge contains the reagents required for the chemiluminescent reaction to take place incorporated into its wells.
The process from sample entry to results can be completed in 2 simple steps, with minimal risk of human error.
No other components are required.
